These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 9745826)
1. [Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide]. Detry-Morel M; De Hoste F Bull Soc Belge Ophtalmol; 1997; 267():157-66. PubMed ID: 9745826 [TBL] [Abstract][Full Text] [Related]
2. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices. Pajic B; Curr Med Res Opin; 2003; 19(2):95-101. PubMed ID: 12740152 [TBL] [Abstract][Full Text] [Related]
3. A trial of dorzolamide for glaucoma. Gillies WE; Brooks AM Ophthalmic Surg Lasers; 1998 Sep; 29(9):728-32. PubMed ID: 9760608 [TBL] [Abstract][Full Text] [Related]
4. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. Maruyama K; Shirato S J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402 [TBL] [Abstract][Full Text] [Related]
6. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. Adamsons IA; Polis A; Ostrov CS; Boyle JE J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861 [TBL] [Abstract][Full Text] [Related]
7. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Nesher R; Ticho U Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130 [TBL] [Abstract][Full Text] [Related]
9. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. Gugleta K; Orgül S; Flammer J Curr Med Res Opin; 2003; 19(4):330-5. PubMed ID: 12841926 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Strohmaier K; Snyder E; DuBiner H; Adamsons I Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691 [TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194 [TBL] [Abstract][Full Text] [Related]
12. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Tamer C; Oksüz H Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574 [TBL] [Abstract][Full Text] [Related]
13. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406 [TBL] [Abstract][Full Text] [Related]
14. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Clineschmidt CM; Williams RD; Snyder E; Adamsons IA Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693 [TBL] [Abstract][Full Text] [Related]
16. Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study. Nagel E; Vilser W; Lanzl I Curr Eye Res; 2005 Feb; 30(2):129-37. PubMed ID: 15814471 [TBL] [Abstract][Full Text] [Related]
17. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. Portellos M; Buckley EG; Freedman SF J AAPOS; 1998 Feb; 2(1):43-7. PubMed ID: 10532366 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Ozturk F; Ermis SS; Inan UU Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215 [TBL] [Abstract][Full Text] [Related]
19. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Gudmundsdóttir E; Stefánsson E; Bjarnadóttir G; Sigurjónsdóttir JF; Gudmundsdóttir G; Masson M; Loftsson T Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3552-4. PubMed ID: 11006251 [TBL] [Abstract][Full Text] [Related]
20. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Martínez A; Sánchez M Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]